The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.

Taking an endpoint of Ct level >35 as a negative result and comparing the two groups, the ivermectin group showed that 43% (20/46) reached this point at day 6 versus 33% (13/39) of the placebo group; however, it did not reach statistical significance ( P = 0.34).

also in 111,027 other papers